Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer....
Main Authors: | Alexandra Thomas, Eric D. Routh, Ashok Pullikuth, Guangxu Jin, Jing Su, Jeff W. Chou, Katherine A. Hoadley, Cristin Print, Nick Knowlton, Michael A. Black, Sandra Demaria, Ena Wang, Davide Bedognetti, Wendell D. Jones, Gaurav A. Mehta, Michael L. Gatza, Charles M. Perou, David B. Page, Pierre Triozzi, Lance D. Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-10-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1490854 |
Similar Items
-
Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types
by: Eric D. Routh, et al.
Published: (2020-02-01) -
Predominance of HIV-1 Subtype A and D Infections in Uganda
by: Dale J. Hu, et al.
Published: (2000-12-01) -
An evaluation of the pathological gambling pathways model using the National Epidemiological Survey on Alcohol and Related Conditions (NESARC)
by: Dowd, Damien A.
Published: (2012) -
An evaluation of the pathological gambling pathways model using the National Epidemiological Survey on Alcohol and Related Conditions (NESARC)
by: Dowd, Damien A.
Published: (2012) -
Molecular biological subtypes of breast cancer in BRCA1 mutation carriers
by: N. I. Pospekhova, et al.
Published: (2021-01-01)